Sucrobind Tablet

Sucrobind Tablet contains sucroferric oxyhydroxide as its active component and is classified as a phosphate binder. It is indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. Hyperphosphatemia is characterised by abnormally elevated phosphate levels in the blood, a frequent complication of CKD. This medicine contains iron, which may provide benefit to patients with CKD who commonly develop iron deficiency anaemia. The combination of iron supplementation and phosphate binding addresses both iron deficiency and supports red blood cell formation.

Sucrobind Tablet should not be used in patients with a known allergy to sucroferric oxyhydroxide or any of its components. Allergic reactions may range from mild to severe and include symptoms such as rash, itching, swelling, dizziness, or difficulty breathing. Patients with iron overload disorders, including haemochromatosis, or those receiving high-dose intravenous iron therapy should use Sucrobind Tablet with caution. Safety and effectiveness in paediatric patients have not been established, as the medicine has not been extensively studied in this population.

Treatment of high phosphate levels in the blood

Sucrobind Tablet is a medication that effectively lowers elevated phosphate levels in the blood, primarily in patients with chronic kidney disease (CKD) who are on dialysis. By binding to dietary phosphate in the gastrointestinal tract, this medication prevents its absorption into the bloodstream, thereby reducing the overall phosphate burden. This helps to manage hyperphosphatemia, a common complication of CKD, and minimize associated risks such as bone disease and cardiovascular complications.

To use Sucrobind Tablet, follow the instructions provided by your healthcare professional or the guidelines on the medication packaging. Typically, this medication is taken orally as chewable tablets with meals or shortly after eating. The dosage and frequency of administration will depend on your specific medical condition and individual needs. It is important to chew the tablets thoroughly before swallowing. You may consult your healthcare provider for alternative administration options if you have difficulty chewing.

Sucrobind tablets cause some side effects like all medications, although not everyone will experience them. Serious: Allergic reaction Breathlessness Black stools Common: Diarrhea Discolored feces (usually dark or black) Constipation Nausea Vomiting Stomach pain or discomfort Indigestion or heartburn

When taking Sucrobind Tablet, it is important to note that allergic reactions are rare, but when to occur it requires immediate medical attention for symptoms like rash, itching, swelling, difficulty breathing, or dizziness develop. This medication contains iron and may contribute to iron overload, particularly in at-risk individuals, necessitating regular monitoring of iron levels. Caution should be exercised in individuals with gastrointestinal disorders. The safety during pregnancy, breastfeeding, and in pediatric patients has not been well established. Precautions should be taken to minimize the risk of tooth discoloration by performing good oral hygiene practices. Regular communication with healthcare providers is essential to address concerns and promptly report any concerning symptoms or side effects.